Device Trial Radar · NCT05691023
VNS-REHAB At-Home - Post-Market Study for Using the Vivistim System® at Home
Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- MicroTransponder Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 19, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm post-market study of up to 150 participants, using up to 50 mobile therapists to conduct up to 36-hours at-home therapy. The study will assess at-home therapy implementation instead of an in-clinic therapy implementation for patients who are commercially implanted with the Vivistim System. Patients will be consented for eligibility if appropriate to be implanted with the Vivistim System per the indications for use (The MicroTransponder® Vivistim® Paired VNS™ System is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.). Study participation includes receiving rehabilitation therapy paired with VNS, provided at the patient's home by a therapist, along with self-activated VNS. All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment, although they may be consented prior to implant. It should be noted that the implant surgery is not part of the study.
Conditions
- Ischemic Stroke
- Upper Extremity Problem
Interventions
Vivistim SystemDevice
Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
Primary outcomes
What the sponsor says the trial is designed to measure.
- In-Home therapist timeTime frame: within 18 weeks (after 36 hours of therapy)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Moxie OT
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.